A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver Function
Status:
Completed
Trial end date:
2004-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is 1) to investigate the single-dose pharmacokinetics of immediate
release (IR) paliperidone, after oral administration, in patients having moderate hepatic
impairment compared to patients having normal hepatic function, 2) to document the plasma
protein binding and disposition of the enantiomers of paliperidone, and 3) to evaluate the
tolerability and safety profile of IR paliperidone in both patient populations.
Phase:
Phase 1
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.